Page 92 - GTM-2-3

Global Translational Medicine HPLC-UV lacosamide quantification

lacosamide in other biological matrices, such as saliva appropriate informed consent form to participate in the
[24]
or urine . quantification of lacosamide during routine clinical care.
[25]
5. Conclusion Consent for publication

The proposed HPLC-UV analytical method has This work includes anonymized data from patients who
demonstrated specificity for the target analyte and has have signed the appropriate informed consent form to
demonstrated adequate accuracy, precision, and linearity participate in lacosamide quantification during routine
within the clinically relevant concentration range. clinical care, as well as authorization to include these
Therefore, it holds value to be used in pharmacokinetic data for research and publication as long as anonymity is
studies and therapeutic drug monitoring of lacosamide preserved.
due to its simplicity, short analysis duration, appropriate
sensitivity, and cost-effectiveness. Availability of data

Acknowledgments Data used in this work can be made available to the readers
by contacting the corresponding author.
We would like to thank ARGENOMICS and FUNDACION
INVESTIGAR for helping us to afford the equipment References
qualification. We also thank Dr. Augusto Garcia Vargas, 1. Beydoun A, D’Souza J, Hebert D, et al., 2009, Lacosamide:
Dr. Emiliana Seminara, and Dr. Patricia Coffey for being Pharmacology, mechanisms of action and pooled efficacy
involved in patient follow-up. and safety data in partial-onset seizures. Expert Rev
Neurother, 9: 33–42.
Funding
https://doi.org/10.1586/14737175.9.1.33
This work is part of a research project supported by the
University of Buenos Aires, UBACyT 2018–2022 Code: 2. EMA European Medicines Agency, 2022, Vimpat Product
Monograph, Available from: https://www.ema.europa.eu/en/
20020170100734BA. medicines/human/EPAR/vimpat [Last accessed on 2023 Jan 09].
Conflict of interest 3. Kawasaki Y, Sendo T, 2016, Monitoring of the blood
concentrations of antiepileptic drugs (TDM). Rinsho Byori,
The authors declare they have no competing interests. 64: 1373–1380.

Author contributions https://doi.org/10.1002/ana.25641
Conceptualization: Angeles Gloria Rodriguez Basso, 4. Aícua-Rapún I, André P, Rossetti AO, et al., 2020,
Guillermo Federico Bramuglia Therapeutic drug monitoring of newer antiepileptic drugs:
Formal Analysis: Angeles Gloria Rodriguez Basso A randomized trial for dosage adjustment. Ann Neurol,
Funding Acquisition: Guillermo Federico Bramuglia 87: 22–29.
Investigation: María Cecilia Kravetz, Damian Consalvo https://doi.org/10.1002/ana.25641
Methodology: María Cecilia Kravetz 5. Landmark CJ, Johannessen SI, Patsalos PN, 2020,
Project administration: Maria Sylvia Viola Therapeutic drug monitoring of antiepileptic drugs: Current
Resources: Mariano Núñez status and future prospects. Expert Opin Drug Metab Toxicol,
Supervision: Angeles Gloria Rodriguez Basso, Damian 16: 227–238.
Consalvo https://doi.org/10.1080/17425255.2020.1724956
Validation: Nicolás Martín Barrionuevo, Florencia Ayelén
Fernandez. 6. Czornyj L, Guido PC, Bramuglia G, et al., 2018, High
Writing – original draft: Angeles Gloria Rodriguez Basso, incidence of persistent subtherapeutic levels of the most
María Cecilia Kravetz common AEDs in children with epilepsy receiving
Writing – review & editing: Maria Sylvia Viola, Florencia polytherapy. Epilepsy Res, 148: 107–114.
Ayelén Fernandez, Guillermo Federico Bramuglia https://doi.org/10.1016/j.eplepsyres.2018.09.008
7. Kumar B, Modi M, Saikia B, et al., 2017, Evaluation of brain
Ethics approval and consent to participate pharmacokinetic and neuropharmacodynamic attributes
The study was approved by IRB “Comité de Ética en of an antiepileptic drug, lacosamide, in hepatic and renal
Investigación Clínica y Maternidad Suizo Argentina” impairment: Preclinical evidence. ACS Chem Neurosci,
(ethical approval code: C0004-P00033). This work includes 8: 1589–1597.
anonymized data from patients who have signed the https://doi.org/10.1021/acschemneuro.7b00084

Volume 2 Issue 3 (2023) 10 https://doi.org/10.36922/gtm.1265